Other
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products; cell cultures, whether or not modified: > Antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes: > Antisera and other blood fractions > Other
Duty Rate (from China)
Articles the product of any country, as provided for in subdivision (aa)(ii) of U.S. note 2 to this subchapter
Products classified under HTS 3002.12.00.90
Human Immunoglobulin G (IgG) Concentrate
A purified fraction of human blood plasma containing high levels of Immunoglobulin G antibodies, used therapeutically to treat primary immunodeficiencies and autoimmune disorders. It falls under HTS 3002.12.0090 as an immunological product derived from blood fractions, prepared for therapeutic use via biotechnological purification processes. This excludes simple blood products without specific immunological modification.
Cytomegalovirus (CMV) Hyperimmune Globulin
Hyperimmune plasma fraction enriched with CMV-specific antibodies for preventing CMV infection in transplant patients. Falls under HTS 3002.12.0090 as an other blood fraction/antisera prepared for prophylactic use through plasma fractionation. It meets the definition of immunological products from human blood.
Botulinum Toxin Type A Immune Globulin
Antitoxin derived from human plasma fractions containing antibodies against botulinum toxin, used to treat infant botulism. Classified in HTS 3002.12.0090 as an immunological blood fraction for therapeutic neutralization of toxins. It involves biotech purification of specific antisera.
Tetanus Immune Globulin (TIG)
Human blood fraction providing passive immunity against tetanus toxin for wound management. Under HTS 3002.12.0090 as other blood fraction antisera prepared for therapeutic use. Involves hyperimmunization and plasma fractionation.
Hepatitis B Immune Globulin (HBIG)
Plasma-derived antibodies specific to hepatitis B surface antigen for post-exposure prophylaxis in high-risk cases. Classifies in HTS 3002.12.0090 as an immunological blood fraction/antiserum. Biotechnological pooling and purification ensure specificity.
Varicella Zoster Immune Globulin (VZIG)
Human immune globulin enriched for varicella-zoster virus antibodies to prevent severe chickenpox in immunocompromised patients. HTS 3002.12.0090 for other specific antisera from blood fractions. Prepared via donor plasmapheresis and affinity purification.
Anti-Rh(D) Immunoglobulin Injection
A blood fraction containing antibodies against Rh(D) antigen, administered prophylactically to prevent hemolytic disease in newborns. Classified in HTS 3002.12.0090 as an antiserum derived from human plasma via biotechnological processes for therapeutic use. It targets specific immunological responses rather than general blood components.
Monoclonal Antibody Infliximab Biosimilar
A biotechnologically produced chimeric monoclonal antibody targeting TNF-alpha, used to treat inflammatory conditions like Crohn's disease. It qualifies under HTS 3002.12.0090 as an immunological product (per chapter note) obtained via biotech processes from blood fraction-inspired cell cultures. This covers modified proteins regulating immune processes.
Rabies Immune Globulin (Human)
Passive antibody preparation from human plasma of vaccinated donors, used post-exposure prophylaxis for rabies. HTS 3002.12.0090 covers this as other antisera/blood fractions for prophylactic therapeutic use. Biotech processes ensure high potency against rabies virus.
IVIG for Guillain-Barré Syndrome
Intravenous immunoglobulin pooled from thousands of donors, used therapeutically for Guillain-Barré and other neuropathies. Falls under HTS 3002.12.0090 as modified blood fraction immunological product. Bioprocessing includes pathogen reduction for safety.